https://www.prnewswire.com/news-releases/transcend-therapeutics-receives-breakthrough-therapy-designation-for-tsnd-201-methylone-for-the-treatment-of-ptsd-302501928.html
Transcend Therapeutics Receives Breakthrough Therapy Designation for TSND-201 (methylone) for the...
/PRNewswire/ -- Transcend Therapeutics, a clinical-stage biotechnology company that develops medicines to treat neuropsychiatric diseases, today announced...
transcend therapeuticsbreakthrough therapytsnd 201receives